Strong YoY Growth, Flat Quarter—The Market Smells the Sequential Problem
Reported numbers matched call claims exactly: ₹1,477 Cr revenue (+22% YoY), ₹180 Cr PAT (+60% YoY). Yet the stock fell 2.91% on day 1 and 4.81% by day 3. The reason is buried in the 'strongest quarter ever' framing—quarter-on-quarter, revenue grew just 0.4% and profit declined 10.7%.
+22%
₹1,477 Cr; exceeded by exact call claim
+0.4%
Flat quarter despite 'strongest ever' framing
+59.8%
₹180 Cr; call rounds to +60%
-10.7%
Profit declined despite YoY enthusiasm
22.9%
+256 bps YoY; driven by complex generics mix (39%→50%)
On the earnings screen, Q1 FY-2027 looked like a blowout. Revenue ₹1,477 Cr and PAT ₹180 Cr both hit their call forecasts exactly. Margins expanded 256 basis points year-on-year. Management called it the 'strongest quarter ever.' And yet, on day 1 post-announcement, the stock fell 2.91%. By day 3, it was down 4.81%. The market heard what management didn't lead with: quarter-on-quarter, revenue grew just 0.4% and PAT declined 10.7%. That gap between the YoY narrative and the sequential reality is the story of this quarter.
Claims vs. what holds up
Revenue grew 22% to ₹1,477 Cr
Delivered ₹1,476.8 Cr, +22.0% YoY confirmed
Supported
PAT grew 60% to ₹180 Cr
Delivered ₹180 Cr, +59.8% YoY (call rounds to 60%)
Supported
Gross margin expanded 74 bps YoY
Consistent with EBITDA margin +256 bps YoY; no conflict
Supported
Complex generics grew to 50% of finished dosages from 39% YoY
Confirmed; mix shift driving 256 bps EBITDA expansion
Supported
Strongest Q1 ever
True on YoY (+22% revenue, +60% PAT); false on QoQ (+0.4% revenue, -10.7% PAT)
Overstated (YoY bias)
Europe growth strong year-on-year
Confirmed YoY; sequential softness intentional due to pricing/cost pressures
Supported but qualified
Peptide CDMO $50M revenue by mid-FY29 with 30%+ EBITDA
Quantified and feasible; Q1 showed CHF 5M (~₹40 Cr run-rate) with ₹-12 Cr EBITDA loss
Credible long-term; lumpy near-term
What changed on this call
Peptide CDMO guidance hardened materially. Prior guidance (FY26 call): 'PAT positive on annual basis FY27.' This call: '$50 million revenue run-rate with 30%+ EBITDA margins by mid-FY29, anchored by 3 customer wins at $10M+ each.' The target is now quantified and time-bounded—a material upgrade in specificity. Complex generics mix jumped to 50% of finished dosages (from 39% YoY), now the margin engine driving 256 bps EBITDA expansion. Gagillapur facility status unchanged—7 of 8 facilities have clean regulatory inspection reports, but the Gagillapur facility remains pending FDA clearance with 9 applications queued behind it. Capex guidance reaffirmed at ₹600 Cr for FY27; Genome Valley facility investment completed, next phase is digitalization and modular growth at existing facilities.
The bull-bear ledger
22% YoY revenue growth (₹1,477 Cr) anchored by strong NA demand and formulations
60% YoY PAT growth (₹180 Cr) with EBITDA margin +256 bps—quality expansion
ROCE 18% (up from 17.6% Q4) and expanding on back of margin and capital efficiency
Net debt only ₹1,012 Cr (~0.07x EBITDA)—essentially debt-free and self-funding capex
Operating cash flow ₹387 Cr in Q1; capex ₹89 Cr—free cash generation ₹298 Cr
Peptide CDMO milestone hardened to $50M by mid-FY29; 3 new customer wins initiated Q1
Sequential revenue +0.4%, PAT -10.7%—momentum loss masked by YoY framing
Gagillapur FDA clearance still pending (binary event); 9 applications queued behind it
Peptide CDMO Q1 showed ₹-12 Cr EBITDA loss despite CHF 5M (~₹40 Cr run-rate) revenue
Raw material inflation 'quite high'; Europe supply intentionally held due to pricing power constraints
Genome Valley and peptide GLS facility utilization 'very low'; crossing 50% only by year-end
Capex-heavy FY27 (₹600 Cr); ROCE expansion benefits deferred into FY28+
Risks, ranked by severity
Gagillapur FDA clearance still pending
HighBinary event. Remediation claimed on-track (330+ audits in 2 years, no critical observations); yet clearance timing unknown. 9 applications—ADHD, sodium oxybate (sole first-to-file), oncology—queued behind it. Delay compounds sequential weakness and undermines FY27 growth guidance.
Raw material inflation + pricing power constraint
HighManagement acknowledged RM costs 'quite high.' Europe supply intentionally held due to inability to pass pricing on legacy generic 5 business. If inflation persists, EBITDA margin guidance of 22–23% is at risk. Gross margin expansion from mix may not fully offset.
Sequential revenue plateau (revenue +0.4%, PAT -10.7% QoQ)
HighFY27 growth guidance deferred ('growth will continue'; specific number withheld). If Q2 is also flat or negative, credibility of the 22% YoY growth continuing into FY27 deteriorates sharply.
Peptide CDMO quarterly lumpiness and project dependency
MediumQ1 showed ₹-12 Cr EBITDA loss on CHF 5M revenue. Long cycle times and project-to-product mix variation cause volatility. PAT positive target for FY27 assumes strong H2; risk if projects slip into FY28.
New facility capacity utilization drag
MediumGenome Valley (complex generics) and GLS (peptide) both 'very low' utilization; expected to cross 50% only by year-end. Capex-heavy (₹511 Cr remaining in FY27) with ROCE expansion deferred.
Litigation-dependent product launch timelines
MediumDyanavel and Adzenys (ADHD controlled substances) timelines management cannot disclose due to IP litigation. 9 of 18 pending US approvals are litigation-based. No visibility on commercialization pace.
How the street is positioned
The post-result stock move tells the story better than any earnings call. Granules delivered ₹1,477 Cr revenue and ₹180 Cr PAT—exactly as guided. Yet the stock fell 2.91% on day 1 post-announcement and extended losses to 4.81% by day 3. At ₹833.55, it now trades 8.39% below its all-time high of ₹909.9, though still up 57.3% from its 52-week low of ₹529.85. RSI at 42.4 is neutral—not yet oversold—suggesting scope for further weakness if momentum doesn't recover. However, FII ownership rose 1.76 percentage points QoQ to 15.31%, indicating foreign institutions are nibbling on the dip. This is a vote of confidence in the long-term strategy (peptide CDMO, oncology pipeline) despite near-term headwinds. The market's read is clear: strong YoY growth is real, but sequential stasis and Gagillapur uncertainty make near-term visibility weak.
1 · Q2 FY27: Gagillapur FDA inspection and clearance decision
The lynchpin. Clearance would unlock 9 applications (ADHD, sodium oxybate, oncology formulations) for launch. Delay compounds sequential weakness. Management claims readiness 'every single day'; betting markets should front-load this catalyst.
2 · Q2 sequential revenue growth—the momentum test
Q1's +0.4% QoQ is not convincing. If Q2 revenue is >2–3% QoQ, momentum is back and 'continued FY27 growth' is credible. If flat again, pricing pressure is structural and Gagillapur becomes make-or-break.
3 · H2 FY27: Peptide CDMO revenue and profitability ramp
PAT positive target for FY27 assumes strong H2 after Q1's ₹-12 Cr EBITDA loss. Watch for sequential peptide revenue uplift and EBITDA improvement. H2 has historically been stronger than H1.
4 · FY28 (starts Apr 2027): First oncology self-developed product launch
Pipeline validation. 9–13 oncology products in development; first commercial launch signals execution risk and addressable market traction. Long-term value driver but not near-term earnings impact.
Granules India delivered a fundamentally sound quarter: margins expanding, cash generation strong, and long-term strategy credible (peptide CDMO $50M target, oncology pipeline, complex generics mix). But the sequential momentum is unmistakably flat, and the 'strongest quarter ever' framing was an optical choice—emphasizing YoY while downplaying QoQ weakness (+0.4% revenue, -10.7% PAT). The market smelled this correctly and sold off 4.8% by day 3.
Rating: Hold. The bull case exists (Gagillapur clearance, peptide H2 ramp, FY28 oncology launches), but timing is uncertain and near-term momentum is at risk from RM inflation and pricing constraints. A holder should wait for either (a) Gagillapur clearance announcement, or (b) Q2 sequential revenue growth >2–3%. Until then, the stock is priced fairly at an 8.39% discount to its all-time high.
The number to track from here: Q2 sequential revenue growth. If flat again, Gagillapur is make-or-break.
Strong YoY growth masks sequential flatness; Gagillapur clearance is near-term pivotal
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit capex budget (₹89 Cr Q1 vs ₹600 Cr FY27), on-track peptide PAT positive, but sequential momentum deteriorating and margin guidance at risk if RM inflation persists.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong YoY fundamentals (22% revenue, 60% PAT, 18% ROCE) anchored by complex generics shift and peptide CDMO 100% growth. However, sequential momentum is fading (QoQ PAT -10.7%, revenue +0.4%) and Gagillapur clearance—critical for 9 pending approvals—remains binary. Pricing pressures evident; management intentionally held Europe supply due to cost inflation. Long-term strategy compelling (peptide $50M target, oncology pipeline) but near-term earnings visibility weak.
₹1476.8 Cr
Revenue · +22% YoY₹180 Cr
Reported PAT · +59.8% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue grew 22% to INR1,477 crores
METDelivered ₹1476.8 Cr, +22% YoY confirmed. Call cites ₹1,477 Cr (rounding).
Profit after tax grew 60% to INR180 crores
METDelivered ₹180.0 Cr, +59.8% YoY (call rounds to 60%). Q4 PAT must have been ~₹112.6 Cr; Q1 shows -10.7% QoQ decline.
Gross margin expanded 74 bps YoY to 65.6%
METNo conflict in delivered result; YoY margin expansion evident from 22.9% EBITDA margin at higher growth.
Complex generics grew to 50% of finished dosages from 39% YoY
METCall claims mix shift driving 74 bps EBITDA margin expansion. Supported by strong YoY growth and EBITDA +256 bps.
Revenue broadly stable QoQ; strong Q4 baseline
OVERSTATEDDelivered ₹1476.8 Cr Q1 vs prior QoQ +0.4% only. Not emphasized on call; contradicts 'strongest ever' framing.
Europe growth strong year-on-year even ex-Senn
METConfirmed YoY; but sequential softness held intentionally due to pricing/cost pressures. Candid admission undermines growth narrative.
Peptide CDMO revenue CHF5 million Q1, expecting H2 stronger
METCHF5M ≈ ₹40 Cr annualized. Call projects PAT positive on annual basis FY27; Q1 showed EBITDA loss ₹12 Cr due to project mix.
Earnings quality
What changed since the last call
Peptide CDMO milestone elaborated
UpgradeFY26 call: 'PAT positive on annual basis FY27'. Now: 'USD 50M revenue by mid-FY29 with 30% EBITDA, 3 customer wins.' Quantified and hardened the target.
Complex generics contribution increased
UpgradeFY26 call implied <50% mix; Q1 FY27 now 50% of finished dosages (from 39% YoY). Driving margin expansion +256 bps.
Gagillapur remediation status unchanged
NeutralStill pending FDA clearance; no new approvals. 7 of 8 facilities have clean EIR but Gagillapur remains blocked. Waiting behind clearance: 9 applications ready.
Capex guidance reaffirmed; Genome Valley complete
NeutralFY27 capex ₹600 Cr on-track (₹89 Cr spent Q1). Genome Valley investment complete; next phase: digitalization, modular growth at existing facilities.
The Q&A
Moderate analyst pressure on sequential softness (Europe hold, peptide Q1 EBITDA loss). Management candid on challenges: acknowledged RM inflation 'quite high', pricing power limited on legacy 5, and peptide lumpiness inherent to project business. On guidance, deflected specific FY27 revenue and margin numbers but quantified long-term peptide target. Overall tone held; no evasion but selective on forward specifics.
FY27 revenue outlook — Nishita Shanklesha, Sapphire Capital
PartialWe are quite excited and positive that the growth will continue. Yes, we are confident it will continue.
Gross margin sustainability — Shashank Krishnakumar, Emkay Global
AnsweredRM pressures are quite high with many challenges. But mix toward complex generics helps. We have every reason to believe it will continue.
Europe growth drivers — Shashank Krishnakumar, Emkay Global
AnsweredPlanned growth in both API and FDF business. Strong demand from products filed in past Europe. Upward trajectory going forward.
Capability-based wins — Sajal Kapoor, Antifragile Thinking
AnsweredComplex products are difficult to make. ADHD products require low dosages and consistency—manufacturing very difficult. Sodium oxybate sole first-to-file, very complex product; many tried and failed.
Peptide CDMO milestone — Sajal Kapoor, Antifragile Thinking
AnsweredUSD 50 million revenue with 30%+ EBITDA somewhere mid-third year from now (mid-FY29) should be run rate. 3 customer wins at $10M+ each proof of concept.
Cash flow from operations jump — Tushar Manudhane, Motilal Oswal
AnsweredNo sequential revenue growth means no additional working capital needed. Substantially reduced receivables with higher USA sales where receivable days are better.
Peptide target timing — Tushar Manudhane, Motilal Oswal
Answered5-year period is the question target. Validation of that number should come in middle of that journey (mid-FY29).
Peptide FY27 revenue guidance — Rashmi Shetty, Dolat Capital
PartialObjective is very single force: turn PAT positive for this year. Quarterly run-rate minimum if multiplied by 4 for annual.
Gagillapur warning letter impact — Tushar Manudhane, Motilal Oswal
AnsweredOnly intentional stop for couple days. Post that never stopped production till date. Demand always there, supply always there. Only new product approvals stopped.
Peptide India capex — Krisha Kansara, Molecule Ventures
AnsweredInitial estimates roughly INR 100 Cr intermediate, INR 200 Cr API investment plan. Will not be realized in first year.
Peptide Q1 EBITDA loss — Krisha Kansara, Molecule Ventures
AnsweredNot a big one-off. Project-to-product mix variation. Opex varies quarter-to-quarter. Long cycle-time projects monetize later in H2.
Genome Valley utilization — Yashika Gogia, Nirzar
AnsweredCurrently utilization levels very low. By year-end expect to cross 50%.
Europe sequential softness — Suhani Singh, Ross Capital
AnsweredNot really demand trend; mix of both. Cost pressures on legacy 5 business. Couldn't pass pricing so held some demand. Intentional hold of supply due to pricing and costing pressures.
Oncology ANDA filings — Sameer Baisiwala, Sakman Capital
AnsweredFiled 2 ANDAs so far. 1 ANDA US, 2 dossiers Europe, ~14 extensions in various countries. 9-13 products in dev across oncology.
GPI facility utilization — Sameer Baisiwala, Sakman Capital
AnsweredCurrently 70% capacity utilization. Large leeway ahead. Small expansion needed by end of '28. GPI products are low volume, high-value; 70% not comparable to large-volume facility.
Litigation product launches — Sameer Baisiwala, Sakman Capital
DodgedThese are litigation-based products. I do not have freedom to talk about timelines.
Guidance
FY27 growth will continue (specific number withheld)
MediumManagement stated confident continued growth given 22% Q1 YoY and strong YoY trajectory. However sequential stasis (+0.4% QoQ) undermines confidence.
EBITDA margins to stay in 22-23% range
MediumQ1 delivered 22.9% already at high end. Mix help from complex generics expected to offset RM inflation, but pricing power limited (Europe hold evident).
FY27 capex ₹600 Cr (₹89 Cr spent Q1; ₹511 Cr remaining)
HighGenome Valley completed. Remaining capex for digitalization, modular growth at existing, peptide intermediate (INR 100 Cr) and API (INR 200 Cr) spread over multiple years.
Risks the call surfaced
Regulatory - Gagillapur clearance
HighFDA inspection awaited. 9 applications queued for launch pending clearance. No approval yet despite 7 other facilities EIR-clean. Delay extends revenue unlock.
Margin pressure - RM inflation
HighManagement acknowledged RM inflation 'quite high' with challenges in supply chain costs (freight, packing). Europe business intentionally held supply due to inability to pass pricing. Margin guidance 22-23% at risk.
Sequential momentum - revenue plateau
MediumRevenue essentially flat QoQ (+0.4% only); PAT down -10.7% QoQ. Q1 dubbed 'strongest ever' based on YoY metrics, masking QoQ stasis. Sequential momentum loss suggests growth headwinds.
Peptide CDMO volatility
MediumQ1 peptide EBITDA showed INR -12 Cr loss despite CHF 5 Mn revenue (~₹40 Cr run-rate annualized). Project mix, long cycle times cause quarterly lumpiness. PAT positive target FY27 assumes strong H2.
Capacity utilization drag
MediumGenome Valley complex generics facility and Peptide GLS facility both at 'very low' utilization. Expected to cross 50% by year-end only. Capex-heavy FY27 (₹600 Cr guided) with returns deferred.
Litigation-dependent launches
MediumMultiple controlled substance products (Dyanavel, Adzenys, sodium oxybate) timing dependent on litigation/IP expiry. Management cannot disclose timelines. 9 of 18 pending USA approvals are IP-based.
Management
Score 7/10. Clear and structured; candid on challenges (RM inflation, Europe hold, peptide lumpiness). Selective disclosure on litigation products and specific FY27 revenue guidance. Uses narrative of 'strongest Q1 ever' to frame YoY strength while downplaying QoQ flatness. Strong track record: capex on-target (₹89 Cr Q1), Gagillapur remediation on-schedule (awaiting FDA), complex generics mix shift delivering (11 pp, 256 bps margin). Peptide CDMO target quantified and tracked. Guided 22-23% margins but Q1 already at 22.9%; margin guidance at risk if RM inflation continues.
1 · Q2 FY27 (Aug–Sep 2026)
FDA inspection of Gagillapur facility; clearance of facility unlocks 9 pending approvals
2 · H2 FY27
Peptide CDMO revenue ramp expected to drive PAT positive; peptide H2 historically stronger than H1
3 · FY28 (starts Apr 2027)
First oncology self-developed product launch (Vizag facility); 9-13 oncology products in pipeline
Long-term strategy compelling (peptide $50M target, oncology pipeline) but near-term earnings visibility weak.
Granules Q1: consolidated PAT ₹180 Cr, ~30% adjusted YoY as operating margin expands to 23%
PAT +59.77% YoY · revenue +22.04% · margins expanding · beat vs street
₹1,476.77 Cr
+22.04% YoY
₹179.96 Cr
+59.77% YoY
12.17%
+3pp YoY
₹7.26
Granules India opened FY27 with a clean, operationally strong June quarter. Consolidated revenue rose 22.0% YoY to ₹1,476.77 Cr and net profit came in at ₹179.96 Cr (EPS ₹7.26). The headline PAT growth of +59.8% YoY flatters the picture: the year-ago Q1 FY26 base carried a net exceptional loss of ~₹25.9 Cr (Senn Chemicals acquisition costs and a GPI litigation settlement, partly offset by a ₹10.4 Cr US Pharma disposal gain), whereas this quarter is free of one-offs — so the underlying, adjusted PAT growth is closer to ~30%. Even on that cleaner basis the print is strong, because it is margin-led: operating margin expanded to ~23.0% from 18.25% a year ago and net margin to 12.19% from 9.18%, i.e. profit growth ran well ahead of the topline.
Q1 FY-2027 vs prior quarters
The drivers sit on the operating lines rather than below them — cost of materials and other expenses grew slower than revenue, lifting the gross-to-EBITDA bridge, while finance costs actually eased YoY (₹21.1 Cr vs ₹23.8 Cr). Sequentially the read is softer: revenue was flat QoQ (+0.4% vs ₹1,470.61 Cr) and PAT fell 10.7% off a seasonally strong Q4 that also carried a ₹15.9 Cr exceptional gain and a slightly lower tax rate; margin gave back ground versus Q4's 25.02% OPM. The consolidated-vs-standalone gap is now wide and widening — standalone PAT was just ₹71.75 Cr on ₹801.88 Cr revenue — reflecting the newly consolidated overseas subsidiaries (Senn AG, Granules Pharma GmbH and Canada) and the US-facing Granules Pharmaceuticals Inc. Consolidated is the number the market will anchor on.
The stock went into the print at ₹895.8, up 13.8% over the past month of trading.
Management enters FY27 focused on achieving sustained U.S. FDA readiness at the Gagillapur facility, scaling new product contributions, and accelerating the shift to complex generics. While no specific revenue or margin guidance was provided due to external cost uncertainties, the company aims for its peptide CDMO busi
Against expectations, there is no published quarter-specific consensus (results landed with today's July 21 board meeting and 5:00 PM call); against the analyst frame of 15-20% PAT growth for full-year FY27, this first quarter runs ahead of pace. Management gave no formal revenue or margin guidance on the prior (Q4) call — only ~₹600 Cr FY27 capex, broadly stable net debt, and an aim for the peptide CDMO (Ascelis) to be PAT-positive on an annual basis — so this print can only be judged as consistent with that disciplined, profitable-growth posture, which it is. No management press release was extracted with this filing.
What to watch
W1
Gagillapur USFDA warning letter (Feb 2025) still open under remediation — resolution is the key swing factor for US supply and margins
W2
Peptide CDMO (Ascelis) reaching annual PAT-positive per management's stated FY27 aim — track through the year
W3
Whether OPM recovers toward Q4's 25.02% from this quarter's ~23.0%, and net debt stays stable against ~₹600 Cr FY27 capex
Statement in Rs millions, converted to Cr (÷10). Q1FY27 has NO exceptional items (clean); year-ago Q1FY26 consol carried net exceptional LOSS of Rs25.9cr (Senn transaction costs + GPI litigation settlement, partly offset by US Pharma disposal gain Rs10.4cr), and Q4FY26 carried Rs15.9cr exceptional GAIN — both distort reported YoY/QoQ. Consol scope widened by new subs (Senn AG Apr'25, Granules Pharma GmbH & Canada Nov'25). Limited review, unaudited. All checks pass.